Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Abnormal Proliferation02:23

Abnormal Proliferation

4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

5.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The novel hypomethylating agent NTX-301 reprograms epigenetic and Hippo signaling pathways and exhibits pre-clinical activity in venetoclax-resistant and TP53-mutant AML.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Favorable tolerability of asciminib <i>versus</i> ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Haematologica·2026
Same author

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal of hematology & oncology·2026
Same author

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

相关实验视频

Updated: May 9, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K

身体TP53突变驱动T和NK细胞在AML中的功能障碍,并且可以通过重新激活野生类型p53来挽救.

Li Li, Muharrem Muftuoglu, Edward Ayoub

    medRxiv : the preprint server for health sciences
    |April 29, 2025
    PubMed
    概括

    在T细胞中TP53突变驱动了急性髓性白血病 (AML) 的免疫逃脱,损害了CAR-T细胞治疗. 重生突变p53恢复T细胞功能,为TP53突变AML提供新的治疗策略.

    更多相关视频

    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
    08:34

    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

    Published on: April 13, 2015

    10.1K
    Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
    17:59

    Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

    Published on: April 3, 2011

    12.2K

    相关实验视频

    Last Updated: May 9, 2025

    Yeast As a Chassis for Developing Functional Assays to Study Human P53
    14:57

    Yeast As a Chassis for Developing Functional Assays to Study Human P53

    Published on: August 4, 2019

    9.5K
    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
    08:34

    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

    Published on: April 13, 2015

    10.1K
    Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
    17:59

    Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

    Published on: April 3, 2011

    12.2K

    科学领域:

    • 在瘤学瘤学.
    • 免疫学 免疫学 免疫学
    • 遗传学 是一个遗传学.

    背景情况:

    • 免疫疗法改善了淋巴瘤和骨髓瘤的治疗结果.
    • TP53-突变性急性髓性白血病 (AML) 仍然是一个治疗挑战.
    • 在AML患者的免疫细胞中TP53突变的作用在很大程度上是未知的.

    研究的目的:

    • 研究来自AML患者的免疫细胞中TP53突变的存在和功能影响.
    • 探索TP53突变对T细胞功能和CAR-T细胞治疗的影响.
    • 评估p53活性化作为TP53-突变AML的治疗策略.

    主要方法:

    • 用单细胞多组和表型分析来确定T和NK细胞中的TP53突变.
    • 用TP53突变设计的化学抗原受体T (CAR-T) 细胞被创建以评估功能后果.
    • 进行了体外和体内实验 (PDX小鼠模型) 实验,以评估CAR-T细胞功能和治疗疗效.
    • 使用小分子p53活性剂来评估其恢复突变p53CAR-T细胞功能的能力.

    主要成果:

    • 在AML患者的T细胞和NK细胞中发现了TP53突变.
    • 突变TP53的T细胞显示细胞毒性降低,疲劳标记增加 (PD-1,TIGIT,TIM-3).
    • 工程突变的p53 CAR-T细胞表现出细胞因子分泌和瘤溶解受损,显示出明显的疲劳表型.
    • 在AML模型中,p53的重新激活挽救了CAR-T细胞的功能,减少了疲劳标记,并改善了AML模型的存活率.

    结论:

    • 突变TP53的T细胞是AML免疫逃生的一个新型驱动器.
    • 准免疫细胞中的TP53突变对于克服AML治疗耐药性至关重要.
    • 选择性p53重新激活为TP53-突变AML免疫疗法提供了一个有前途的治疗途径.